Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States
Other
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
Patients with endometriosis-related pain preferred elagolix 200 mg twice daily over leuprolide across all evaluated scenarios, with preferences sensitive to hot flashes and pregnancy risks but not bone fracture risk.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
INTRODUCTION: We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain.
AREA COVERED: Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating elagolix (150 mg/day and 200 mg/twice-daily dosages) and leuprolide for the treatment of moderate to severe endometriosis-related pain. Sensitivity analyses were conducted by varying the range of risk for pregnancy-related problems, moderate to severe hot flashes, and bone fracture across scenarios.
EXPERT OPINION: The 200 mg twice daily dosage of elagolix is more likely to be preferred over leuprolide by patients with moderate to severe endometriosis-related pain in all scenarios explored in the evaluation and sensitivity analyses. The probability that an average respondent would select a treatment was sensitive to increases in risk of moderate to severe hot flashes for leuprolide and possible variations in the risk of pregnancy-related problems for both treatments but was not influenced by an increased risk of bone fracture.
CONCLUSIONS: Patients' preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (22)
- Advances in the management of endometriosis: an update for clinicians via openalex
- Baseline Burden of Endometriosis-Associated Pain among Women in Two Phase 3 Elagolix Studies [10Q] via openalex
- Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA via openalex
- Current and Emerging Therapeutics for the Management of Endometriosis via openalex
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results via openalex
- Differences in characteristics among 1,000 women with endometriosis based on extent of disease via openalex
- Elagolix: First Global Approval via openalex
- How to Understand the Complexity of Endometriosis-Related Pain via openalex
- Management of endometriosis-associated pain via openalex
- Patient Preferences for Endometriosis Pain Treatments in the United States via openalex
- Peripheral changes in endometriosis-associated pain via openalex
- Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women via openalex
- Rethinking endometriosis care: applying the chronic care model via a multidisciplinary program for the care of women with endometriosis via openalex
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex
- Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study via openalex
- W2043018121 via openalex
- W2121619367 via openalex
- W2367707061 via openalex
- W2896492055 via openalex
- W2048709304 via openalex
Cited by (7)
- Fertilizing role of leuprolide acetate in assisted human reproduction among infertile patients with endometriosis 2026
- Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women 2024
- A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain 2023
- Endometriosis in the Mouse: Challenges and Progress Toward a 'Best Fit' Murine Model 2022
- Endometriosis in the Mouse: Challenges and Progress Toward a 'Best Fit' Murine Model 2022
- Analysis of the clinical efficacy of leuprolide acetate in the treatment of obese patients with endometriosis and its role on the expression of MIF gene 2022
- Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 2021
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:29:04.095004+00:00
- unpaywall
- last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0
· commercial use OK